Completed PHASE1 INTERVENTIONAL 1-arm NCT04530604

Defibrotide Therapy for SARS-CoV2 (COVID-19) Acute Respiratory Distress Syndrome (ARDS)

Defibrotide Therapy for SARS-CoV2 Acute Respiratory Distress Syndrome (ARDS)

Sponsor: Gregory Yanik

Conditions Acute Respiratory Distress Syndrome COVID COVID-19 Sars-CoV2

Interventions Defibrotide

Updated 8 times since 2020 Last updated: Jun 28, 2022 Started: Oct 1, 2020 Primary completion: Mar 26, 2021 Completion: Apr 9, 2021

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1 clinical study on Acute Respiratory Distress Syndrome and COVID, this trial is completed. The trial is conducted by Gregory Yanik and has accumulated 8 data snapshots since 2020. Infectious disease trials contribute critical data for public health response and treatment development.

Status Flow

Change History

8 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jun 2023 — Jul 2024 [monthly]

Completed PHASE1
Dec 2021 — Jun 2023 [monthly]

Completed PHASE1

Status: Active Not Recruiting → Completed
Sep 2021 — Dec 2021 [monthly]

Active Not Recruiting PHASE1

Status: Recruiting → Active Not Recruiting

▶ Show 3 earlier versions

Jan 2021 — Sep 2021 [monthly]

Recruiting PHASE1
Nov 2020 — Jan 2021 [monthly]

Recruiting PHASE1

Status: Not Yet Recruiting → Recruiting
Sep 2020 — Nov 2020 [monthly]

Not Yet Recruiting PHASE1

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Gregory Yanik
Jazz Pharmaceuticals

Data source: University of Michigan

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Ann Arbor, United States